CROI 2017: Advances in antiretroviral therapy

Joyce Jones, Barbara S. Taylor, Hong Van Tieu, Timothy J. Wilkin

Research output: Contribution to journalReview article

Abstract

The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) featured exciting preclinical data on investigational antiretroviral agents with good in vitro efficacy and long half-lives. Investigational medications, including bictegravir, demonstrated excellent efficacy and tolerability, as did dual-agent therapy with dolutegravir paired with rilpivirine or with lamivudine. Dolutegravir monotherapy proved inadvisable due to virologic failure and resistance. The gap between high- and low-income settings along the HIV care continuum is narrowing, with Zimbabwe, Malawi, and Zambia approaching the 90-90-90 targets established by the joint United Nations Programme on HIV/AIDS (UNAIDS), whereas communities in the Southern United States are falling behind. Innovative strategies to improve outcomes include 2-way text messaging, home-based HIV testing, peer navigation, and New York City’s realignment of services into comprehensive sexual health programs. A high prevalence of resistance was documented in low- and middle-income settings and policy considerations were modeled to address increasing resistance rates. Novel resistance mutations to integrase strand transfer inhibitors and nucleoside analogue reserve transcriptase inhibitors were identified, but the clinical implications are unclear and require further investigation. Several studies provided insights on dosing and safety of antiretroviral therapy to prevent mother-tochild transmission through pharmacokinetic analysis. A special session devoted to Zika virus included a study of its effects on the central nervous system and a promising animal study of a Zika vaccine.

Original languageEnglish (US)
Pages (from-to)51-67
Number of pages17
JournalTopics in antiviral medicine
Volume25
Issue number2
StatePublished - May 1 2017

Fingerprint

Retroviridae Infections
Opportunistic Infections
Rilpivirine
HIV
Accidental Falls
Text Messaging
Anti-Retroviral Agents
Zambia
Malawi
Integrases
Zimbabwe
Continuity of Patient Care
Lamivudine
United Nations
Reproductive Health
DNA-Directed RNA Polymerases
Nucleosides
Acquired Immunodeficiency Syndrome
Therapeutics
Vaccines

Keywords

  • AIDS
  • Antiretroviral
  • CROI
  • HIV
  • Investigational drugs
  • Therapy
  • Treatment strategies
  • Zika

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases
  • Virology

Cite this

Jones, J., Taylor, B. S., Tieu, H. V., & Wilkin, T. J. (2017). CROI 2017: Advances in antiretroviral therapy. Topics in antiviral medicine, 25(2), 51-67.

CROI 2017 : Advances in antiretroviral therapy. / Jones, Joyce; Taylor, Barbara S.; Tieu, Hong Van; Wilkin, Timothy J.

In: Topics in antiviral medicine, Vol. 25, No. 2, 01.05.2017, p. 51-67.

Research output: Contribution to journalReview article

Jones, J, Taylor, BS, Tieu, HV & Wilkin, TJ 2017, 'CROI 2017: Advances in antiretroviral therapy', Topics in antiviral medicine, vol. 25, no. 2, pp. 51-67.
Jones J, Taylor BS, Tieu HV, Wilkin TJ. CROI 2017: Advances in antiretroviral therapy. Topics in antiviral medicine. 2017 May 1;25(2):51-67.
Jones, Joyce ; Taylor, Barbara S. ; Tieu, Hong Van ; Wilkin, Timothy J. / CROI 2017 : Advances in antiretroviral therapy. In: Topics in antiviral medicine. 2017 ; Vol. 25, No. 2. pp. 51-67.
@article{d587350136014fbab6c6a5e869a82db7,
title = "CROI 2017: Advances in antiretroviral therapy",
abstract = "The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) featured exciting preclinical data on investigational antiretroviral agents with good in vitro efficacy and long half-lives. Investigational medications, including bictegravir, demonstrated excellent efficacy and tolerability, as did dual-agent therapy with dolutegravir paired with rilpivirine or with lamivudine. Dolutegravir monotherapy proved inadvisable due to virologic failure and resistance. The gap between high- and low-income settings along the HIV care continuum is narrowing, with Zimbabwe, Malawi, and Zambia approaching the 90-90-90 targets established by the joint United Nations Programme on HIV/AIDS (UNAIDS), whereas communities in the Southern United States are falling behind. Innovative strategies to improve outcomes include 2-way text messaging, home-based HIV testing, peer navigation, and New York City’s realignment of services into comprehensive sexual health programs. A high prevalence of resistance was documented in low- and middle-income settings and policy considerations were modeled to address increasing resistance rates. Novel resistance mutations to integrase strand transfer inhibitors and nucleoside analogue reserve transcriptase inhibitors were identified, but the clinical implications are unclear and require further investigation. Several studies provided insights on dosing and safety of antiretroviral therapy to prevent mother-tochild transmission through pharmacokinetic analysis. A special session devoted to Zika virus included a study of its effects on the central nervous system and a promising animal study of a Zika vaccine.",
keywords = "AIDS, Antiretroviral, CROI, HIV, Investigational drugs, Therapy, Treatment strategies, Zika",
author = "Joyce Jones and Taylor, {Barbara S.} and Tieu, {Hong Van} and Wilkin, {Timothy J.}",
year = "2017",
month = "5",
day = "1",
language = "English (US)",
volume = "25",
pages = "51--67",
journal = "Topics in antiviral medicine",
issn = "2161-5853",
publisher = "International Antiviral Society",
number = "2",

}

TY - JOUR

T1 - CROI 2017

T2 - Advances in antiretroviral therapy

AU - Jones, Joyce

AU - Taylor, Barbara S.

AU - Tieu, Hong Van

AU - Wilkin, Timothy J.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) featured exciting preclinical data on investigational antiretroviral agents with good in vitro efficacy and long half-lives. Investigational medications, including bictegravir, demonstrated excellent efficacy and tolerability, as did dual-agent therapy with dolutegravir paired with rilpivirine or with lamivudine. Dolutegravir monotherapy proved inadvisable due to virologic failure and resistance. The gap between high- and low-income settings along the HIV care continuum is narrowing, with Zimbabwe, Malawi, and Zambia approaching the 90-90-90 targets established by the joint United Nations Programme on HIV/AIDS (UNAIDS), whereas communities in the Southern United States are falling behind. Innovative strategies to improve outcomes include 2-way text messaging, home-based HIV testing, peer navigation, and New York City’s realignment of services into comprehensive sexual health programs. A high prevalence of resistance was documented in low- and middle-income settings and policy considerations were modeled to address increasing resistance rates. Novel resistance mutations to integrase strand transfer inhibitors and nucleoside analogue reserve transcriptase inhibitors were identified, but the clinical implications are unclear and require further investigation. Several studies provided insights on dosing and safety of antiretroviral therapy to prevent mother-tochild transmission through pharmacokinetic analysis. A special session devoted to Zika virus included a study of its effects on the central nervous system and a promising animal study of a Zika vaccine.

AB - The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) featured exciting preclinical data on investigational antiretroviral agents with good in vitro efficacy and long half-lives. Investigational medications, including bictegravir, demonstrated excellent efficacy and tolerability, as did dual-agent therapy with dolutegravir paired with rilpivirine or with lamivudine. Dolutegravir monotherapy proved inadvisable due to virologic failure and resistance. The gap between high- and low-income settings along the HIV care continuum is narrowing, with Zimbabwe, Malawi, and Zambia approaching the 90-90-90 targets established by the joint United Nations Programme on HIV/AIDS (UNAIDS), whereas communities in the Southern United States are falling behind. Innovative strategies to improve outcomes include 2-way text messaging, home-based HIV testing, peer navigation, and New York City’s realignment of services into comprehensive sexual health programs. A high prevalence of resistance was documented in low- and middle-income settings and policy considerations were modeled to address increasing resistance rates. Novel resistance mutations to integrase strand transfer inhibitors and nucleoside analogue reserve transcriptase inhibitors were identified, but the clinical implications are unclear and require further investigation. Several studies provided insights on dosing and safety of antiretroviral therapy to prevent mother-tochild transmission through pharmacokinetic analysis. A special session devoted to Zika virus included a study of its effects on the central nervous system and a promising animal study of a Zika vaccine.

KW - AIDS

KW - Antiretroviral

KW - CROI

KW - HIV

KW - Investigational drugs

KW - Therapy

KW - Treatment strategies

KW - Zika

UR - http://www.scopus.com/inward/record.url?scp=85019744041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019744041&partnerID=8YFLogxK

M3 - Review article

C2 - 28598790

AN - SCOPUS:85019744041

VL - 25

SP - 51

EP - 67

JO - Topics in antiviral medicine

JF - Topics in antiviral medicine

SN - 2161-5853

IS - 2

ER -